Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the journal of Epilepsy & Behavior Case Reports has accepted for publication a case report on the efficacy of CPP-115 in a child with refractory infantile spasms.

The case report presents a child treated with CPP-115 through an investigational new drug protocol who experienced a significant reduction of seizures with no evidence of retinal dysfunction. The research paper made the following conclusions:

  • The case study suggests sustained efficacy and tolerability of CPP-115 in treating epileptic spasms
  • It reported reduction in seizure frequency and documented improvements in the EEG interictal and ictal record temporally associated with CPP-115 initiation for this patient
  • It reported that in the context of refractory infantile spasms and associated morbidity, mortality, and poor neurodevelopmental outcomes, CPP-115 is potentially a promising alternative to vigabatrin therapy

Prior to treatment with CPP-115, the patient had failed ten drugs and the ketogenic diet, and had approximately 100 seizures per day. One year after starting CPP-115 and coming off of clobazam and vigabatrin, the patient’s reported seizures have seen a marked reduction in frequency and his cognition and behavior have improved.

“There is a significant unmet medical need in the area of refractory infantile spasms, as parents of children who have infantile spasms have a very difficult choice when it comes to treatment options, weighing both drug-related risks and adequate treatment,” said Patrick J. McEnany, Chairman and CEO of Catalyst. “Our pediatric epilepsy experts advise us that approximately half of the children diagnosed with infantile spasms are refractory to the medications approved for the treatment of infantile spasms.” (Original Source)

Shares of Catalyst Pharmaceutical Partners closed last Friday at $0.99, down $0.03 or -2.94%. CPRX has a 1-year high of $4.51 and a 1-year low of $0.51. The stock’s 50-day moving average is $0.92 and its 200-day moving average is $0.88.

On the ratings front, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on CPRX, in a report issued on June 14. According to, Fein has a yearly average return of 16.1%, a 53.0% success rate, and is ranked #135 out of 4163 analysts.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder. 


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts